AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06470763
Drug: ANV600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ANV600 administered by intravenous (IV) infusion
Trial: NCT05513001
Drug: LOU064 (blinded)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LOU064 (blinded) active treatment
Trial: NCT05513001
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT06438367
Drug: [14C]TGRX-326
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healthy subjects will be given TGRX-326 60 mg orally on day 1.
Trial: NCT05176951
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral inhalation using a capsule-based dry powder inhaler device.
Trial: NCT05148286
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For the control group, 30 cc per kg of crystalloid will be administered according to the usual practice. The treating physicians can choose the type of fluid, such as balanced fluid or isotonic saline.
Trial: NCT06102837
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: conventional treatment in clinical
Trial: NCT05525637
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Match placebo tablets, once daily in the evening
Trial: NCT06702202
Drug: Mixture of local anesthetics
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Marcaine® (bupivacaine HCl) 0,5% and Xylocaine® (Lidocaine HCL) 2% = 2:1 Given in Femoropopliteal block group (Group F)
Trial: NCT05111626
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mFOLFOX6: 5-fluorouracil, leucovorin, and oxaliplatin will be administered as IV infusion.~OR CAPOX: oxaliplatin will be administered as IV infusion and capecitabine will be administered orally.
Trial: NCT06438172
Drug: HCP1803-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take it once daily for 8 weeks orally.
Trial: NCT06438172
Drug: RLD2001-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take it once daily for 8 weeks orally.
Trial: NCT06438172
Drug: HPP2003-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo drug. Take it once daily for 8 weeks orally.
Trial: NCT06568614
Drug: SYH2039
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SYH2039 dosed orally
Trial: NCT05395481
Drug: LY3849891
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT05395481
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT06365918
Drug: VG2025
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given by Intraperitoneal
Trial: NCT06132035
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient will instill daily 1 package of Placebo eye drops in the study eye \[self-administered\] using the single use tear-off disposable packaging
Trial: NCT04431999
Drug: Fractionated blood products transfusion
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Severe trauma patients with a life threatening bleeding will be managed with 3 packed red blood cells (PRBCs), 3 lyophilised plasma units and 1 dose of platelets for the 1st. The 2nd pack will consist of 3 packed red blood cells (PRBCs) and 3 lyophilised plasma units. Then, the later pack will consist of 3 packed red blood cells (PRBCs), 3 plasma units and 1 dose of platelets.
Trial: NCT05313152
Drug: TAVO103A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAVO103A single ascending dose IV infusion.
Trial: NCT04484818
Drug: Placebo Administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT04818632
Drug: AZD9833
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part A: AZD9833 monotherapy dose escalation.
Trial: NCT04818632
Drug: AZD9833
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part B: AZD9833 monotherapy dose expansion
Trial: NCT06566794
Drug: Caffeine Tablet
RxNorm normalized name: Caffeine Tablets
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0,5 x 100 mg tablet (50 mg caffeine).
Trial: NCT06566794
Drug: Flurbiprofen Capsels
RxNorm normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 x 10 mg tablet.
Trial: NCT06566794
Drug: Simvastatin tablets
RxNorm normalized name: Simvastatin Tablets
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 x 10 mg tablet.
Trial: NCT06566794
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 x placebo tablets in the Placebo Phase/Arm
Trial: NCT06566794
Drug: Diclofenac
RxNorm normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 x 50 mg tablet (three times daily for three days)
Trial: NCT05562791
Drug: [68Ga]PSMA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 68Gallium PSMA-PET/CT imaging within 10 days after standard of care FDG-PET/CT.
Trial: NCT05269706
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo (Twice Daily)
Trial: NCT06249152
Drug: QLS-111, 0.015%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QLS-111 eyedrops applied QPM for 14 days the BID for 14 days.
Trial: NCT06249152
Drug: QLS-111, 0.030%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QLS-111 eyedrops applied QPM for 14 days the BID for 14 days.
Trial: NCT06249152
Drug: QLS-111 vehicle ophthalmic solution
RxNorm normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle drops applied QPM for 14 days the BID for 14 days.
Trial: NCT06174922
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone for 4 months
Trial: NCT04838405
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT06701396
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsule
Trial: NCT05178316
Drug: JZP150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration of JZP150 once daily in the morning
Trial: NCT05178316
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration of placebo once daily in the morning
Trial: NCT05384119
Drug: Aromatase inhibitor (AI)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet
Trial: NCT06007391
Drug: Nicotinamide
RxNorm normalized name: Nicotinamide
DrugBank: Nicotinamide (DB02701)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: nicotinamide 3g per day
Trial: NCT04641273
Drug: BAY1817080
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, intake orally.
Trial: NCT04641273
Drug: Placebo for BAY1817080
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, intake orally.
Trial: NCT04665700
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05187182
Drug: CA-4948
RxNorm normalized name: Ca 2+
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Provided by Curis, Inc.
Trial: NCT05187182
Drug: mFOLFOX7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care
Trial: NCT05260255
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: add on placebo ( 2 cap ) for 12 weeks
Trial: NCT05800366
Drug: Doxorubicin Hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Per standard care, via IV infusion
Trial: NCT05800366
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Per standard care, via IV infusion
Trial: NCT05463731
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV or SC
Trial: NCT05724745
Drug: 3. Reversibility test with salbutamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reversibility test with salbutamol administered using a pressurized metered dose bottle and an inhalation chamber at a dosage of 100 μg, 4 times (i.e., 400 μg in total).
Trial: NCT06307678
Drug: Calcium Hydroxide
RxNorm normalized name: Calcium Hydroxide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The samples were taken from the interstitial fluid of the apical tissues using 3 paper points before medicament placement.~Calcium hydroxide based medicament was placed in the canals using a file at a distance of 1 or 2 mm less than the root canal length.~At the second appointment, medicamentswere removed, and second samplingwas performed using the same method.~The RANKL/OPG, TNF alpha, TGF beta, PGE2 levels were measured by the enzyme-linked immunosorbent assay, and their ratio was calculated.
Trial: NCT05327023
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: HLA-matched: 50 mg/kg IV once daily over 2 hours on days +3 and +4a Cyclophosphamide will be dosed according to ideal body weight. HLA haploidentical: 25 mg/kg IV once daily over 2 hours on days +3 and +4a Cyclophosphamide will be dosed according to ideal body weight.
Trial: NCT05683548
Drug: REP 2139-Mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: REP 2139-Mg is the magnesium chelate complex of REP 2139
Trial: NCT05116709
Drug: BAT6005 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Six dose groups were set up, including 10mg (initial dose) group, 30mg group, 100mg group, 300mg group, 600mg group and 900mg group, respectively.
Trial: NCT05413902
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Provide this drug as part of a multimodal pharmacologic regimen for pain management including multiple drugs mentioned in the group description.
Trial: NCT05413902
Drug: Epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Provide this drug as part of a multimodal pharmacologic regimen for pain management including multiple drugs mentioned in the group description.
Trial: NCT05473858
Drug: OraVerse Injectable Product
RxNorm normalized name: OraVerse Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: injection of oraverse,
Trial: NCT06282445
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000mg/m2, po, bid, d1-14, Q3W Maintenance therapy: 1250mg/m2, po, bid, d1-14, Q3W
Trial: NCT06365853
Drug: Prednisolone acetate ophthalmic suspension 1% eye drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administration of prednisolone acetate ophthalmic suspension 1% eye drops as prescribed by the treating physician.
Trial: NCT05331885
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo contains only excipients
Trial: NCT06036004
Drug: Intranasal OXT
RxNorm normalized name: OXT-101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Syntocinon® contains the synthesized peptide OXT in a solution formulated to promote absorption through the nasal mucosa. Additional ingredients are E216 (propyl-4-hydroxybenzoate), E218 (methyl-4-hydroxybenzoate), and chlorobutanol hemihydrate. One bottle contains 5 ml, i.e., 200 IU of OXT in total. Each 0.1 ml nasal insulation delivers 4 IU of oxytocin.~OXT (24 IU twice daily) is given for 28 (± 2) days of treatment.
Trial: NCT06434363
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given by vein (IV)
Trial: NCT06188026
Drug: ethinylestradiol/levonorgestrel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptive is taken as tablet daily composed of 30 μg ethinylestradiol and 150 μg levonorgestrel.
Trial: NCT05308940
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once-daily subcutaneous injection, on Day 1 in SAD stage
Trial: NCT05308940
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once-daily subcutaneous injection, on Days 1-7 in MAD stage
Trial: NCT05364021
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo for LP352 administered three times daily, orally or through G-tube
Trial: NCT06575933
Drug: MK-1084
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration
Trial: NCT06760819
Drug: BAY2927088
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet, oral
Trial: NCT05463094
Drug: Test Glucophage® XR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive single oral dose of Test GXR RM tablet under fasted or fed conditions.
Trial: NCT05463094
Drug: Reference Glucophage® XR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive single oral dose of Reference GXR RM tablet under fasted or fed conditions.
Trial: NCT05753189
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo: Proprietary Vehicle Solution
Trial: NCT06261450
Drug: CBD Oral Solution (eCBD system Target)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants receive orally 6 ml of CBD Oral Solution (100 mg / ml; 60 mg / kg; max 600 mg of CBD) followed by 6 ml of a placebo composed of the inactive ingredients of CBD Oral Solution 3 weeks later.
Trial: NCT06261450
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants receive orally 6 ml of a placebo composed of the inactive ingredients of CBD Oral Solution followed by 6 ml of Oral CBD Solution (100 mg / ml; 60 mg / kg; max 600 mg of CBD)
Trial: NCT06704113
Drug: meloxicam 7,5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of analgesic efficacy of Meloxicam Vs Ibuprofen
Trial: NCT05788237
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% saline for injection
Trial: NCT06269146
Drug: Placebo Pill
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will match the study drug in mode of administration, color, size, and taste.
Trial: NCT05488847
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: preoperative pain medication given to all patients
Trial: NCT05488847
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative and discharge pain medication given to all patients
Trial: NCT05488847
Drug: Ropivicaine
RxNorm normalized name: Ropivicaine-Sufentanil Citrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative pain medication given to all patients
Trial: NCT05488847
Drug: Epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraoperative pain medication given to all patients
Trial: NCT05488847
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraoperative pain medication given to all patients
Trial: NCT05488847
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Discharge pain medication given to all patients
Trial: NCT05412394
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liquid, 5mg/kg per week, for one year
Trial: NCT06232902
Drug: QL1101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3mg/kg, single intravenous infusion over 90 min (± 5 min) on first day
Trial: NCT06486441
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered intravenously
Trial: NCT05076591
Drug: IMM2902
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a recombinant bispecific monoclonal antibody with high affinity to the dual targets, HER2 and CD47
Trial: NCT04852328
Drug: CUE-101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CUE Biopharma will supply CUE-101, which will be provided free of charge to the patient.
Trial: NCT06311760
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered as IV infusion.
Trial: NCT04931147
Drug: RXC007
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RXC007 will be administered in the form of oral capsules at selected doses starting at 2 mg to 4 of the 6 participants within each cohort in Part A and Part B. For Part A, dosing frequency is one single dose on one occasion and for Part B, dosing frequency is single doses once daily for 14 days. If required, following dose escalation data review, dosing frequency and duration may be modified in Part B.~All participants in Part C (24) will receive active RXC007 in the form of oral capsules as single doses.
Trial: NCT04931147
Drug: RXC007 Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The matching placebo for RXC007 will be administered in the form of oral capsules matched to the number of active RXC007 capsules at each dose level to 2 of the 6 participants within each cohort in Part A and Part B. For Part A, dosing frequency is one placebo dose on one occasion and for Part B, dosing frequency is single placebo doses once daily for 14 days. If required, following dose escalation data review, dosing frequency and duration may be modified in Part B.~There is no placebo intervention for Part C of the study.
Trial: NCT06268145
Drug: ECC5004
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose tablet of 50 mg of the current tablet formulation (F1) or new tablet formulation (F2) administered orally.
Trial: NCT06322407
Drug: standardized drug treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topiramate(Topiramate, Xi'an Yangsen Pharmaceutical Co., Ltd) will be started at a low dose and then increased gradually until optimally effective, side effects become intolerable, or the maximum recommended dose is reached. During the 4-week up-titration phase, the intention will increase dose weekly in 25 mg increments with the aim of reaching 50-100 mg/day. Ibuprofen((Fenbid, Tianjin Shike Pharmaceutical Co., Ltd)will be chosen as acute treatment, but no more than 10 times per month to avoid medication overuse headache.
Trial: NCT05216328
Drug: Macrogol Only Product in Oral Dose Form
RxNorm normalized name: Macrogol only product in oral dose form
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Information already included in arm/group description.
Trial: NCT05469854
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose, oral tablets
Trial: NCT05559580
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT06736574
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Tablet
Trial: NCT06788080
Drug: BioRBC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous biotin-labeled RBCs will be transfused to study participants
Trial: NCT06782646
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will take placebo tablets, a look-alike substance that contains no drug, (500 mg orally twice a day) for 12 weeks.
Trial: NCT06485401
Drug: ADC189
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 45 mg per tablet, oral administration, single dose.
Trial: NCT06342947
Drug: ALG-055009
RxNorm normalized name: DRESSING,BIATAIN ALG 2IN X 2IN C#3705
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Softgel Capsule
Trial: NCT06342947
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Softgel Capsule
Trial: NCT05330143
Drug: ASC22 1mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASC22 single-dose of 1mg/kg vials administered subcutaneously once 4 week.
Trial: NCT05330143
Drug: ASC22 2.5mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASC22 single-dose of 2.5mg/kg vials administered subcutaneously once 4 week.
Trial: NCT04650087
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will take placebo twice a day, once in the morning and once in the evening for 30 days. Participants will be contacted (electronic or telephone) 2 days after starting the study medication and will continue up to day 90 after starting study treatment. Followup will occur from the time of discharge through the 30 day study period with contacts at 2 days, 10 days, 20 days and 30 days after discharge. Two additional study contacts will take place 45 days and 90 days after discharge.
Trial: NCT05330143
Drug: Antiretroviral Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard antiretroviral therapy including Integrase inhibitors (INSTIs)
Trial: NCT05330143
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% saline vials administered subcutaneously once 4 week.
Trial: NCT06564493
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The total dose of cyclophosphamide is 120 mg/kg, administered over 2 days on days -4 and -3.
Trial: NCT06106828
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered by SC injection
Trial: NCT05047783
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo